Application
Dot blot analysis of Phospho-APG4A-S100 Antibody (Cat.# AP3455a) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.| Product Name | Phospho-ATG4A-S100 Antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Modification | p-S100 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | DB |
| DB:1:500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | APG4A, AUTL2 |
|---|---|
| Alternative Names | ATG4A APG4A AUTL2 Cysteine protease ATG4A AUT-like 2 cysteine endopeptidase Autophagin-2 Autophagy-related cysteine endopeptidase 2 Autophagy-related protein 4 homolog A |
| Molecular Weight(MW) | 45378 Da |
| Function | Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes. Preferred substrate is GABARAPL2 followed by MAP1LC3A and GABARAP |
| Tissue Specificity | Widely expressed, at a low level, and the highest expression is observed in skeletal muscle and brain. Also detected in fetal liver |
| Cellular Localization | Cytoplasm (Probable). |
| Entrez Gene | 115201 |
|---|
Application
Dot blot analysis of Phospho-APG4A-S100 Antibody (Cat.# AP3455a) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.| Application Notes | DB:1:500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified rabbit polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with the control and phosphorylated peptides. The phospho-specific antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. |
